Phase 2 N=138 Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Melanoma
Primary: Immunologic Response Rate — 7; 1; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=110 Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
Melanoma
Primary: Rate of Relapse-free Survival at 18 Months — 29; 28; 27; 26 Participants
Phase 2 N=104 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
High-Risk Melanoma
Primary: Immunologic Response Rate — 2; 0; 0; 3 Participants
Phase 2 N=64 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Phase 2 N=26 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Phase 2 N=4 Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Melanoma · Skin Cancer
Primary: Complete Response Rates for Patients With Metastatic Melanoma — 0; 0; 0; 0 Participants
Phase 2 N=34 Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Uveal Melanoma
Primary: Relapse Free Survival (RFS) Rate at 32 Months — 50 Probability
Phase 2 N=80 Lovastatin in Treating Patients At High Risk of Melanoma
Precancerous Condition · Stage 0 Melanoma · Stage I Melanoma
Primary: Histopathologic Regression of Target Atypical Nevi With Treatment - Pathologist 1's Evaluation — 0.50; -0.12 score
Phase 2 N=24 Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Melanoma · Skin Cancer
Primary: Clinical Tumor Regression. — 0; 0; 6; 0 Participants
Phase 2 N=44 High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Melanoma
Primary: Objective Response Rate — 25 percentage of participants
Phase 2 N=37 Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients
Phase 2 N=3 Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants
Phase 2 N=4 Radiation and Combination Immunotherapy for Melanoma
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Phase 2 N=20 Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Phase 2 N=170 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Melanoma · Neoplasm Metastasis
Primary: Clinical Response — 0; 0; 0; 0 Participants
Phase 2 N=10 Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Skin Cancer · Metastatic Melanoma
Primary: Response — 0; 0; 8; 2 Participants
N/A N=1,000 Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access
Melanoma
Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001
Phase 2 N=15 Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Metastatic Melanoma
Primary: Immune Response Rate — 0.29; 0.67 proportion of participants
Phase 2 N=24 Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Phase 2 N=158 Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
N/A N=100 Melanoma Perception and Health Literacy in People of Color
Melanoma
Primary: Number of Participants That Performed Regular Self-Skin Examinations — 8; 16; 23; 25 participants — p=0.048
Phase 3 N=676 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Melanoma · Metastases
Primary: Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone — 9.95…
Phase 2 N=52 Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Phase 2 N=1,009 A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
Phase 2 N=102 Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Metastatic Melanoma · Skin Cancer
Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants
Phase 2 N=17 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Phase 2 N=20 Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients